Check it out on https://t.co/0LdCQCWC28. I have no business relationship with any company whose stock is mentioned in this article. Enzolytics owns 49% of Immunotech Laboratories BG-Europe. Its proprietary methodology for produce fully human monoclonal antibodies may be use to produce therapeutics treatments for name infectious diseases including the Coronavirus. According to their website, they have tested 31 patients. Enzolytics is seeking a Contract Manufacturing Organization (CMO) in the United States to produce the Immunotherapy Treatment to be used as the validation batch in coordination with the Bulgarian regulatory authority and Immunotech BG-Europe. Besides, the competition in the HIV drugs market is significant. Enzolytics Inc. claims to be offering a product with zero toxicity issues, minor side effects, and cost savings. victor lungu - Software Test Analyst - Endava | LinkedIn Disclosure: We have not been compensated for this article/video. Additional details will be disclosed as the transaction progresses. What I find interesting here is that Enzolytics had just 197 shareholders as of December, yet there were tens of thousands of posts about the company across message boards on the internet before retail investor interest gathered pace. Digestix; RCC-33; the Run on Cannabics Pharmaceuticals Inc (OTCMKTS: CNBX), Zero-Emission EV; the Rise of Adomani Inc (OTCMKTS: ADOM), Enzolytics Inc (OTCMKTS: ENZC) Biotech Reversal Underway As ITV-1 Gains Traction, Enzolytics Inc (OTCMKTS: ENZC) Coiled Tight Near 52 Week Lows as Biotech Looks to Disrupt Several Enormous Markets (ITV-1 for HIV, Monoclonal Antibodies & AI), Enzolytics Inc (OTCMKTS: ENZC) Powerful Reversal Underway as Immune Goes International in Booming Nutritional Supplement Market, Enzolytics Inc (OTCMKTS: ENZC) Running Up the Charts After Biotech Outlines Progress and Future Plans (Update on: Artificial Intelligence Diagnostics & ITV-1 and IPF Immune), Enzolytics Inc (OTCMKTS: ENZC) Major Reversal Brewing as Biotech Gains Traction in HIV Market (Update on: ITV-1 EMA Approval, ITV-1, anti-HIV Treatment & IPF Immune US Launch), Enzolytics, Inc. (ENZC) Big Reversal Northbound as Biotech Launches IPF Immune & Plans Immune Therapeutic ITV-1 for Clinical Trials, Your email address will not be published. Please. I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I don't think the previous auditor had the PCAOB designation. Responsible for defining, implementing and managing . With its technology for producing fully human monoclonal antibodies against numerous infectious diseases viruses, including those targeting the HIV-1 virus [http://www.bioclonetics.com/effectiveness.html] and recognizing a significant correlative structure between the HIV virus and the SARS-CoV-2 (COVID-19) virus, BioClonetics has been invited by the National Science Foundation (NSF) to submit an application for funding for development of anti-SARS-Cov-2 monoclonal antibodies using its proprietary technology. 28 universities involved in research. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. PLANO, TX/ ACCESSWIRE/ April 16, 2020/ Enzolytics- is pleased to update shareholders on the current corporate initiatives. Dr. Saggar has served on staff at Holy Name Medical Center in Teaneck, New Jersey since 2007 and currently serves as the Chief of the Department of Infectious Disease, Medical Director of the Institute for Clinical Research, and is the chair of Infection Prevention at Holy Name. Source: Annual Report, In addition, on November 30, 2020, the Zhabilov Trust, the Company's Controlling Shareholder, entered into a Control Block Transfer Agreement, under which the Zhabilov Trust has agreed to transfer 35,100,000 shares of Series A Preferred Stock and 231,000,000 shares of Common Stock (together the "Control Block") to Charles S. Cotropia and other Bioclonetics Designees. Iurii Zama - Senior Project Manager - Techno Test S.r.l. - LinkedIn Enzolytics flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. In order to get its treatment passed by Europeans, Enzolytics, Inc. may need to test hundreds of patients. Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of HIV/AIDS. I searched for "shoes" and flower bouquets showed up. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands. Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. $25,000,000 dollars in research. On December 1, 2020, Enzolytics announced that it merged with BioClonetics Immunotherapeutics, a company with technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Immunotech BG-Europe has a license for the development and commercialization of Enzolytics Patented ITV-1 Technology. IPF is a platform technology that can be used to facilitate a broad range of applications. Source: Press Release. Enzolytics, Inc. Announces Execution of Letter of Intent with The most recent news appears beneficial. We have previously produced monoclonal antibodies against HIV, rabies, influenza A, influenza B, tetanus and diphtheria. However, there are no revenues and its Bulgarian partner denies that Enzolytics has a stake in it. Reunion Neuroscience Inc.s (NASDAQ: REUN) Take-Private Agreement and Its Impact on Mental Health Solutions, Marker Therapeutics, Inc. (NASDAQ: MRKR) Unveils Exciting Pre-Clinical Findings of MT-601 T Cell Therapy in Lymphoma Cells, Aclarion Inc (NASDAQ: ACON): A Breakthrough Partnership, Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI, Wearable Devices Ltd. (NASDAQ: WLDS) Breaking Boundaries with AI, Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment, Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) Secure Partnership, ContraFect Corp (NASDAQ: CFRX): A Low Float Runner, Magoceuticals Inc. (NASDAQ: MGRX) Climbing Up The Charts, Aemetis Inc. (NASDAQ: AMTX) Pioneers Renewable Fuel Market with EPA Approval, GSI Technology, Inc. (NASDAQ: GSIT): Pure AI Play Transforming Semiconductor Memory Solutions for Efficient AI Processing. During that period, he served as a partner in the law firm Sidley Austin LLP in its Dallas office. Immunotech Laboratories BG does not work in any form with Enzolytics Inc. (OTCPK:ENZC). Enzolytics Inc. targets a market that could be close to $37 billion in 2027. of Texas Southwestern Medical School, a Master of Science Degree in Physiological Chemistry from the University of Wisconsin at Madison, Wis., and a Bachelor of Science Degree from the University of Texas at Austin, Texas. According to data from Fintel, the short borrow fee rate currently stands at 3.78%. If you look at their chart from the prior months, the average volume was relatively minuscule sometimes trading as low as 5K shares a day. Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of HIV/AIDS. With 2.7 billion shares, the current market capitalization is larger than $600 million. Enzolytics, Inc. owns licensing rights of the Irreversible Pepsin Fraction peptide molecule for the treatment of HIV/AIDS. Dont expect a lot of long articles. Enzolytics Is Surrounded By Controversy And Could Be Worthless The critical thing to note with this deal between TScan and Amgen is that the cash milestones ensure a cash runway for TCRX, potentially even until they become commercially viable and profitable. He is a healthcare research professional with vast experience and expertise based on his background as an accomplished infectious disease specialist spanning two decades. Enzolytics is seeking a Contract Manufacturing Organization (CMO) in the United States to produce the Immunotherapy Treatment to be used as the validation batch in coordination with the Bulgarian regulatory authority and Immunotech BG-Europe. As mentioned in their Oct 19th PR, they said they would use AI to analyze the 16,000 known sequences of different SARS-Cov-2 viruses using their ( Cl3hmAb ) patented Clone 3. Source: Company's Website. Reveal contacts of top Invitro Diagnostics managers and employees. * $ONFO +76% at market open pic.twitter.com/gOLBZjlqJ2, Commonstock (@JoinCommonstock) May 26, 2023. Now just waiting on $CYTO pic.twitter.com/OfJgNb1ty0. Thereafter, PBMC based in-vitro neutralization studies will be conducted with the Enzolytics ITV-1 peptide in combination with the BioClonetics Clone 3 antibodies. The HIV drug market is extremely competitive. Enverics commitment to innovation extends beyond EB-373. I think Enzolytics is a sell and investors can take advantage of this by shorting the shares. Entering text into the input field will update the search result below, However, I think that article didnt focus enough on the, controversies surrounding the company as well as the. Meet our flagship product: Immunocal More than 430,000,000 portions sold. The market believes that the value of the company's assets is worth much more than the valuation given by accountants. Investors should thoroughly evaluate the companys long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions. In addition, he periodically discusses up-to-the-minute health information, new research findings, and the latest advances in health screenings and medical technology. He also has a private medical practice. and it looks like the drugs are in an early phase of development, so I doubt this business should be worth much at the current time. The company says the study was carried out by Petia Genova-Kalou. Fax: (972)292-9414, View source version on accesswire.com: To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. The flagship compound of the company is named Immune Therapeutic Vaccine-1 (ITV-1) and represents a suspension of Inactivated Pepsin Fraction (IPF) that could be effective in the treatment of HIV/AIDS. Dr. Moss has a Doctor of Medicine Degree from the Chicago Medical School, Chicago, IL, and a Bachelor of Arts degree from SUNY at Stony Brook, NY. I have no business relationship with any company whose stock is mentioned in this article. Enzolytics, Inc. Shares BioClonetics - Markets Insider Entering text into the input field will update the search result below. If the company raises capital, it will be able to easily pay its debts: Enzolytics, Inc. has delivered several announcements which may explain the most recent reaction in the stock price. Just this week Seven countries in Europe are reporting mink-related (because they were first discovered in minks) coronavirus mutations that are much less resistant to antibodies. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Enzolytics is committed to the betterment of health for all mankind and exploring/developing additional applications of its novel immunotherapy compounds to that end. The BioClonetics Clone 3 recombinant mAbs will be combined with the Enzolytics' flagship compound ITV-1 which is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. Dr. Saggar is also an adjunct clinical associate professor at Touro College of Osteopathic Medicine in New York City. I am not receiving compensation for it (other than from Seeking Alpha). million as of time of writing and I think its a sell. However, it is essential to note that Onfolio Holdings operates at a loss. Perform your own due diligence and consult a financial professional before trading. While multi-billion dollar pharmaceutical giants including Eli Lilly antibody may be effective the virus is mutating quickly and will likely escape around it. Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. (f/k/a Eco Petroleum Solutions, Inc. / Immunotech Laboratories, Inc.) from time to time in its periodic reports filed with the SEC. Please disable your ad-blocker and refresh. Please disable your ad-blocker and refresh. BioClonetics Immunotherapeutics, Inc. is a Dallas, Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Enzolytics, Inc. Completes Merger with BioClonetics Immunotherapeutics Mr. Cotropia holds a Bachelor of Science degree with honors in Aerospace Engineering from the University of Texas at Austin and a Juris Doctorate Degree from Cornell University. It recently merged with another biotechnology company, which aims to treat HIV and COVID-19, but there is little information on the matter. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. His experience also extends to designing and conducting Pre-Clinical and Clinical Trials for Drug Development. Enzolytics's Competitors, Revenue, Number of Employees - Owler Assist Immunotech Laboratories BG-Europe in the registration of ImmunH as an Immunomodulator for HIV treatment. I have been investing in stocks since 2007.I have no preference for sectors or countries - I'm as comfortable owning a part of a cement miner in Peru as holding shares in a wheat farming firm in Bulgaria. BioClonetics Immunotherapeutics, Inc. is a Dallas, Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Currently running northbound with power ENZC is one of the most exciting stories in small caps that has gone parabolic in recent days and is nearing $0.0217 price to beat; a break over and its blue skys ahead. BioClonetics Immunotherapeutics, Inc. is a Dallas Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Compared to the ~27M shares traded at the time of writing, thats a massive shift. One technology, invented by Harry Zhabilov, the CSO of the Company, is a patented antiviral peptide that has been tested in clinical studies at the National Center of Infectious and Parasitic. 60 million Series A preferred shares, and 445,180,000 Series B preferred shares as of December 2020. Privacy Policy. exchange agreement, all the liabilities of Immunotech Laboratories, Inc. were assumed by Enzolytics Solutions, Inc. On June 22, 2017, Eco Petroleum Solutions, Inc.(OTC Markets "ECPO" or the "Company") a nnounces that IMMB BG, a subsidiary of Immunotech Laboratories, Inc., the Company's subsidiary, has issued an IPF is a platform technology that can be used to facilitate a broad range of applications. The process will also take a lot of time and financial resources. "The combination of our two companies' proprietary technologies and products is a once in a lifetime opportunity that should benefit both of our organizations letting us achieve more together than we could apart", stated Harry Zhabilov, CEO of ENZC. However, investors must carefully consider the companys financial performance and evaluate its long-term growth potential before making investment decisions. If it's a value stock - great. Collaboration Brings Together TScans Proprietary Target Discovery Platform and Amgens Inflammation Therapeutic Expertise and Research Capabilities. Safe Harbor Statement:This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. from time to time in its periodic reports filed with the SEC. Even if the company gets its treatment approved, the total amount of sales obtained may be lower than expected. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. It is free from major neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today. Moreover, the Company has proprietary methodology needed to produce anti-coronavirus monoclonal antibodies targeting such sites. Interestingly, some traders are surprised it managed to trade such massive volumes early intraday. If ENZC sells equity, the share price may decline. Risky Enzolytics Inc. Delivered Triple-Digit Stock Returns The Companys anti-HIV monoclonal antibody targets an immutable virus site on the HIV virus one that is constant within virtually all 6000 now known different HIV isolates (strains) of the virus. The market believes that the company's treatment is worth more than the accounting value of the debt of Enzolytics Inc. Save my name, email, and website in this browser for the next time I comment. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body. We look forward to discovering how ENZC's ITV-1 treatment can be used with our monoclonal antibody platform to synergistically improve our such antibodies for treating HIV.". I wrote this article myself, and it expresses my own opinions. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. $TCRX #TCRX nice wake up call watch the break above 5.47 to potential 6.25 test pic.twitter.com/FvoAYEFslG, APFK_ASIAN PICASSO. Provide the planning and leadership to the Development Department by ensuring that the appropriate structures, systems, competencies and values are developed in order to meet and exceed the goals of the Marketing plan. Gaurav Chandra, MD, will serve as COO of the merged entity. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. However, the latter has released this statement, disputing the share structure and claiming the ITV-1 clinical trials are its intellectual property. All articles are my opinion - they are not suggestions to buy or sell any securities. These forward-looking statements are made as of the date of this press release, and the Company expressly disclaims any intention or obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Just came out with a competitive AI software that will fight against the tech kings #microsoft #google, Dont Look Down (@M_1Ball) May 26, 2023. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings stock price. - Reviewing and analyzing the system requirement. Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced that the Company's wholly owned subsidiary, Virogentics (), has received the analysis report from the Bulgarian Academy of Sciences determining the protein concentration, native enzyme concentration and peptide . The trading volume rose significantly in September, around the first mentions of BioClonetics. Dr. Gaurav Chandra has a Doctor of Medicine Degree from Albert Einstein College of Medicine, Montefiore, NY, a Bachelor of Medicine degree from Kasturba Medical College, Manipal India, and a Masters in Business Administration Degree from the University of Colorado, Denver, Colorado. Enzolytics currently holds a 49% Interest in Immunotech Laboratories BG-Europe. MONROVIA, Calif.-- (BUSINESS WIRE)--Immunotech Laboratories, Inc. (OTCMARKETS:IMMB) Immunotech Laboratories, Inc. announced today that the Phase I and Phase II field trials in Bulgaria of. Such application to the NSF and a corresponding application to the NIH are now pending. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enverics value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders. In my opinion, investors need to remain cautious. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. 2000 North Central Expressway, Suite 104 Plano, TX 75074 (972)-292-9414 www.enzolytics.com harry@enzolytics.com SIC Code 541711 Annual Report For the Period Ending: December 31, 2021 (the "Reporting Period") As of December the number of shares outstanding of our Common Stock was: outstanding of our Common Stock was: 2,797,935,953. https://www.accesswire.com/606214/Enzolytics-Inc-Announces-Execution-of-Letter-of-Intent-with-BioClonetics-Immunotherapeutics-Inc-With-Additional-Update-on-2020-Initiatives, 1985 - 2023 BioSpace.com. Texas A&M Universities CIADM was one of three centers developed in the U.S. in response to the H1N1 influenza pandemic by BARDA. Enzolytics Inc. Shares Current BioClonetics Immunotherapeutics - Nasdaq Enzolytics says it owns a 49% stake in a Bulgarian company named Immunotech Laboratories ( OTC:IMMB). The company has retained SEC counsel for the purpose of updating all. Phone: (972)292-9414 Plus, lockup expiry is tomorrow, so this is a blatant pump and dump: pic.twitter.com/QnYVoDnqqr, Adam Gefvert, CFA (@Shiningboy) May 26, 2023. However, numerous companies are already selling HIV Drugs. Investors practically all over the internet keep their eye on the stock for potential entry points utilizing various day trading techniques. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. Endava. - Working with Agile methodologies. Looking at the balance sheet, Enzolytics barely had any cash reserves as of September and its shareholders equity and working capital positions were negative. However, the latter has released this statement, disputing the share structure and. We look forward to developing the value of our platform both in this partnership with Amgen and in other autoimmune diseases.. Anderson Hospital and Tumor Institute in Houston, Texas, served as an Internal Medicine Intern at Presbyterian Hospital Dallas, Texas, and completed his internal medicine residency at the Central Texas Medical Foundation, Brackenridge Hospital in Austin, Texas. It will be imperative that produced antibodies target a conserved and immutable site on the virus otherwise the antibody (over time) will be rendered ineffective due to mutation known as virus escape. It is also very beneficial that Enzolytics, Inc. received $1.2 million in new financing: Enzolytics, Inc. today, announced it has received the official filing receipt from the U.S. Patent Office confirming the filing of its patent application for "Nuclear Proteins Isolated from Mammalian Spinal Cord Immune Factor - Pharmaceutical Composition for Treatment" and has received the third tranche of the $1.2 million dollar financing. Enzolytics, Inc. may try to sell equity to finance these new projects. ITV-1 has been shown to modulate the immune system. Harry H. Zhabilov - Biography - MarketScreener.com Adamis Pharmaceuticals, San Diego, CA, March 2017-Present, Chief Medical Officer. The Company has some important people behind it who would not be wasting their time here unless they really believed they had something.
Gola Nordic Sherpa Sneaker,
Love Is Heavenly Victoria Secret,
Funny Things To Be Thankful For,
Lancome La Nuit Tresor Reformulated,
Houses For Rent In Humansville, Mo,
Articles I